Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aceragen Inc ACGN

Healthcare Biotechnology
Aceragen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and... see more

Recent & Breaking News (NDAQ:ACGN)

Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis

Business Wire June 5, 2013

Idera Pharmaceuticals Reports First Quarter 2013 Financial Results

Business Wire May 15, 2013

Idera Announces Presentation of Positive Data from Phase 2 Trial of TLR 7 and 9 Antagonist in Patients with Moderate-to-Severe Plaque Psoriasis

Business Wire May 8, 2013

Idera Pharmaceuticals Announces Closing of Common Share Offering

Business Wire May 7, 2013

Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants

Business Wire May 1, 2013

Idera Announces Clinical Development Progress in Its Autoimmune Diseases Program

Business Wire April 1, 2013

Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Update on Autoimmune Disease Program

Business Wire March 11, 2013

Idera Announces Presentation at AAD Annual Meeting Demonstrating Toll-like Receptor Antagonists Normalize Expression of Inflammatory Genes in Psoriasis Model

Business Wire March 2, 2013

Idera Pharmaceuticals Announces Presentation at American Academy of Dermatology Annual Meeting

Business Wire February 26, 2013

Idera to Present at the 15th Annual BIO CEO and Investor Conference

Business Wire February 5, 2013